2012-09-17 05:59:15 - Recently published research from Global Markets Direct, "Dermatophytosis - Pipeline Review, H2 2012", is now available at Fast Market Research

Global Markets Direct's, 'Dermatophytosis - Pipeline Review, H2 2012', provides an overview of the Dermatophytosis therapeutic pipeline. This report provides information on the therapeutic development for Dermatophytosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dermatophytosis. 'Dermatophytosis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Full Report Details at

- www.fastmr.com/prod/463758_dermatophytosis_pipeline_review_h2_20 ..


Scope

* A snapshot of the global therapeutic scenario for Dermatophytosis.
* A review of the Dermatophytosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Dermatophytosis pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Dermatophytosis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Dermatophytosis pipeline depth and focus of Dermatophytosis therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Dermatophytosis Therapeutic Products under Development, Key Players in Dermatophytosis Therapeutics, Dermatophytosis Pipeline Overview, Dermatophytosis Pipeline, Dermatophytosis Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Dermatophytosis Overview
Therapeutics Development
An Overview of Pipeline Products for Dermatophytosis
Dermatophytosis Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Dermatophytosis Therapeutics - Products under Development by Companies
Companies Involved in Dermatophytosis Therapeutics Development
Valeant Pharmaceuticals International
Stiefel Laboratories, Inc.
Quinnova Pharmaceuticals, Inc.
Bayer AG
Helix BioMedix, Inc.
Almirall, S.A.
Anacor Pharmaceuticals, Inc.
Nitric Biotherapeutics, Inc.
Laboratorio Teuto Brasileiro
Dermatophytosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
HB1275 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IDP 113 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AN2718 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Albaconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LAS41003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nitric Oxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Econazole Nitrate Foam 1% - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bifonazol Spray - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tolnaftate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dermatophytosis Therapeutics - Drug Profile Updates
Dermatophytosis Therapeutics - Dormant Products
Dermatophytosis - Product Development Milestones
Featured News & Press Releases
Apr 12, 2006: Medicis Announces Two Patents Issued for Loprox Gel
Apr 12, 2006: Medicis Announces Two Patents Issued for Loprox Gel
Dec 20, 1999: Medicis Announces FDA Approval of Loprox Gel, 0.77%

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463758&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.